Showing 1 - 20 results of 30,769 for search '(((( 50 ((a decrease) OR (_ decrease)) ) OR ( 25 nm decrease ))) OR ( 12 nn decrease ))*', query time: 0.76s Refine Results
  1. 1
  2. 2
  3. 3

    Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s. by Djaloul Karboua (16510091)

    Published 2023
    “…<p>Scenario (6): Parameter variation (50% decrease)—With 5 N.m load applied at t = 0.3s.…”
  4. 4

    AKT inhibition decreases neuroblast populations. by Maria R. Aburto (186884)

    Published 2012
    “…Otic vesicles were isolated from HH18 chicken embryos, made quiescent and cultured for 20 h in serum-free culture medium without additions (0S, a) or in the presence of IGF-I (10 nM, b), LY294002 (LY, 25 µM, c) or AKTi VIII (AKTi, 50 µM, d). …”
  5. 5
  6. 6

    BKM120 decreases cellular glycolytic metabolic activity in MB cell lines. by Ping Zhao (47228)

    Published 2017
    “…<p>MB cells were treated with BKM120 ranging from 31.25 nM to 4 μM over a course of 48 hours. ATP/cell assays showed a decrease in ATP level per cell after 48 hours of BKM120 treatment, which indicates a decrease in cellular glycolytic metabolic activity in MB cell lines in a dose-dependent manner. …”
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    Knockdown of endogenous DJ-1 leads to decreased DA reuptake. by Beryl Luk (787284)

    Published 2015
    “…(B) The levels of DJ-1 expression was quantified to show significant knockdown of DJ-1 levels in cells transfected with siDJ-1#1 and siDJ-1#3 (50–60% decrease compared to controls), while siDJ-1#2 exhibited a decreasing trend in DJ-1 expression. * P<0.05 vs control group; one-way ANOVA post hoc Tukey test, n = 3. …”
  12. 12
  13. 13
  14. 14

    The estrogen receptor-α agonist PPT decreases cardiac myofilament activation. by Justyna Kulpa (313372)

    Published 2013
    “…<p>Myocardium was treated with the estrogen receptor-α agonist PPT (100 nM) for 1 (A) (N = 9), 2.5 (B) (N = 9), or 5 min (C) (N = 22). …”
  15. 15
  16. 16

    Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<p>VCaP cells were transfected for 72h from 2.5 nM to 50 nM with siRNA TMPRSS2-ERG III, siRNA TMPRSS2-ERG IV or siRNA Control. …”
  17. 17
  18. 18
  19. 19
  20. 20